<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02389946</url>
  </required_header>
  <id_info>
    <org_study_id>BIOFLOW-V</org_study_id>
    <nct_id>NCT02389946</nct_id>
  </id_info>
  <brief_title>Safety and Effectiveness of the Orsiro Sirolimus Eluting Coronary Stent System in Subjects With Coronary Artery Lesions</brief_title>
  <acronym>BIOFLOW-V</acronym>
  <official_title>BIOTRONIK - A Prospective Randomized Multicenter Study to Assess the SaFety and Effectiveness of the Orsiro SiroLimus Eluting Coronary Stent System in the Treatment Of Subjects With up to Three De Novo or Restenotic Coronary Artery Lesions - V</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Biotronik, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Biotronik AG</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Baim Institute for Clinical Research</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Medstar Health Research Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Biotronik, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to assess the safety and efficacy of the Orsiro Sirolimus
      Eluting Coronary Stent System in the treatment of subjects with up to three native de novo or
      restenotic (standard PTCA only) coronary artery lesions compared to the Xience coronary stent
      system.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The BIOTRONIK BIOFLOW-V clinical trial is a prospective, multicenter, randomized, controlled
      trial combining data on the randomized subjects with data from two historical studies by
      employing a Bayesian approach.

      Subjects with CAD that qualify for PCI with stenting will be screened per the protocol
      inclusion and exclusion criteria to achieve a total of up to 1,400 randomized subjects.
      Eligible subjects will be randomized in a 2:1 ratio, stratified by study center, to undergo
      percutaneous coronary revascularization with either the Orsiro Sirolimus Eluting Stent System
      (treatment group) or the Xience Everolimus Eluting Stent System (control group).

      Subjects may receive treatment of up to three target lesions, one or two target lesions per
      target vessel, for a maximum of two target vessels. The target lesion(s) must be de novo or
      restenotic lesion(s) of â‰¤ 36 mm in length in native coronary artery(ies), with a reference
      vessel diameter of 2.25-4.0 mm. Treatment of restenotic lesions is allowed provided that the
      target lesion was previously treated with PTCA only. All treatment with study stents is to be
      performed during a single index procedure. Note: Concurrent treatment of non-target lesions
      during the index procedure is not allowed.

      Randomized subjects will have clinical follow-up at 1 month, 6 months, 12 months and at 2, 3,
      4 and 5 years following the index procedure.

      To assess the non-inferiority of the Orsiro stent compared to the Xience stent, BIOFLOW-V
      randomized subjects will be combined with historical subjects from the BIOFLOW-II and
      BIOFLOW-IV randomized trials employing a Bayesian approach. Only subjects who meet all
      clinical and angiographic eligibility criteria of the BIOFLOW-V trial will be included in the
      analysis.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>May 2015</start_date>
  <completion_date type="Anticipated">April 2021</completion_date>
  <primary_completion_date type="Actual">April 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants With Target Lesion Failure (TLF) at 12 Months Post-Index Procedure by Bayesian Estimation</measure>
    <time_frame>12-Months</time_frame>
    <description>TLF is defined as all cardiac death, target vessel Q-wave or non-Q-wave myocardial infarction (MI), or clinically driven target lesion revascularization (TLR).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Lesions With Device Success</measure>
    <time_frame>Hospital Discharge (6-24 hours post-index procedure)</time_frame>
    <description>Defined as attainment of &lt; 30% residual stenosis of the target lesion using the assigned study stent only.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Lesions With Lesion Success</measure>
    <time_frame>Hospital Discharge (6-24 hours post-index procedure)</time_frame>
    <description>Defined as attainment of &lt; 30% residual stenosis of the target lesion using any percutaneous method.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Procedure Success</measure>
    <time_frame>Hospital Discharge (6-24 hours post-index procedure)</time_frame>
    <description>Defined as attainment of &lt; 30% residual stenosis of the target lesion using the assigned study stent only without occurrence of in-hospital major adverse cardiac events (MACE; composite of all-cause death, Q-wave or non-Q-wave MI, and any clinically-driven TLR).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Myocardial Infarction</measure>
    <time_frame>Hospital Discharge (6-24 hours post-index procedure), 1, 6, 12 months, 2, 3, 4 and 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Myocardial Infarction or Cardiac Death</measure>
    <time_frame>Hospital Discharge (6-24 hours post-index procedure), 1, 6, 12 months, 2, 3, 4 and 5 years</time_frame>
    <description>Anticipated reporting: April 2022.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With MACE and Individual MACE Components</measure>
    <time_frame>Hospital Discharge (6-24 hours post-index procedure), 1, 6, 12 months, 2, 3, 4 and 5 years</time_frame>
    <description>MACE: composite of all-cause death, Q-wave or non-Q-wave MI, and any clinically-driven TLR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With TLF and Individual TLF Components</measure>
    <time_frame>Hospital Discharge (6-24 hours post-index procedure), 1, 6, 12 months, 2, 3, 4 and 5 years</time_frame>
    <description>TLF: composite of cardiac death, target vessel Q-wave or non-Q-wave MI, and any clinically-driven TLR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Target Vessel Failure (TVF) and Individual TVF Components</measure>
    <time_frame>Hospital Discharge (6-24 hours post-index procedure), 1, 6, 12 months, 2, 3, 4 and 5 years</time_frame>
    <description>TVF: composite of cardiac death, target vessel Q-wave or non-Q-wave MI, and any clinically-driven TVR.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Stent Thrombosis</measure>
    <time_frame>Hospital Discharge (6-24 hours post-index procedure), 1, 6, 12 months, 2, 3, 4 and 5 years</time_frame>
    <description>Stent thrombosis according to the Academic Research Consortium criteria.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">1334</enrollment>
  <condition>Coronary Artery Disease</condition>
  <condition>Atherosclerosis, Coronary</condition>
  <condition>Myocardial Ischemia</condition>
  <condition>Ischemic Heart Disease</condition>
  <condition>Acute Coronary Syndrome</condition>
  <condition>Angina Pectoris</condition>
  <arm_group>
    <arm_group_label>Orsiro sirolimus coronary stent system</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intervention with a Orsiro DES.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Xience everolimus coronary stent system</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Intervention with a Xience DES.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Orsiro DES</intervention_name>
    <description>Orsiro is a device/drug combination product composed of two components, a device (coronary stent system including a cobalt chromium stent platform), and a drug product (a formulation of sirolimus) contained in a bioabsorbable polymer coating.</description>
    <arm_group_label>Orsiro sirolimus coronary stent system</arm_group_label>
    <other_name>Orsiro sirolimus coronary stent system</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Xience DES</intervention_name>
    <arm_group_label>Xience everolimus coronary stent system</arm_group_label>
    <other_name>Xience everolimus coronary stent system</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Subject is â‰¥18 years or the minimum age required for legal adult consent in the
             country of enrollment.

          2. Subject is an acceptable candidate for PCI.

          3. Subject is an acceptable candidate for CABG.

          4. Subject has clinical evidence of ischemic heart disease, stable or unstable angina
             pectoris or documented silent ischemia.

          5. Subject is eligible for dual anti-platelet therapy treatment with aspirin plus either,
             clopidogrel, prasugrel, ticagrelor or ticlopidine.

          6. Subject has provided written informed consent.

          7. Subject is willing to comply with study follow-up requirements.

        Each target lesion/vessel must meet all of the following angiographic criteria for the
        subject to be eligible for the trial:

          1. Subject has up to three target lesions in up to two separate target vessels (two
             target lesions in one vessel and one target lesion in a separate vessel).

          2. Target lesion must be de novo or restenotic lesion in native coronary artery;
             restenotic lesion must have been treated with a standard PTCA only.

          3. Target lesion must be in major coronary artery or branch (target vessel).

          4. Target lesion must have angiographic evidence of â‰¥ 50% and &lt; 100% stenosis (by
             operator visual estimate). If the target lesion is &lt; 70% stenosed, clinical evidence
             of ischemia by positive functional study, CT, electrocardiography, FFR, or post
             infarct angina.

          5. TIMI flow &gt; 1.

          6. Target lesion must be â‰¤ 36 mm in length by operator visual estimate.

          7. Target vessel RVD of 2.25-4.0 mm by operator visual estimate.

          8. Target lesion must be treatable with a maximum of two overlapping stents.

        Exclusion Criteria:

          1. Subject has clinical symptoms and/or electrocardiogram (ECG) changes consistent with
             acute ST elevation myocardial infarction (STEMI) within 72 hours prior to the index
             procedure. Hemodynamically stable non-STEMI (NSTEMI) subjects are eligible for study
             enrollment.

          2. Subject is hemodynamically unstable.

          3. Subject is pregnant and/or breastfeeding or intends to become pregnant during the
             duration of the study.

          4. Subject has a known allergy to contrast medium that cannot be adequately
             pre-medicated, or any known allergy to thienopyridine, aspirin, both heparin and
             bivalirudin, L-605 cobalt-chromium (Co-Cr) alloy or one of its major elements (cobalt,
             chromium, tungsten and nickel), acrylic, fluoropolymers, silicon carbide, PLLA,
             sirolimus or everolimus.

          5. Revascularization of any target vessel within 9 months prior to the index procedure or
             previous PCI of any non-target vessel within 30 days prior to the index procedure.

          6. Planned treatment of a lesion not meeting angiographic inclusion and exclusion
             criteria during the index procedure or after the index procedure.

          7. Planned surgery within 6 months of index procedure unless dual antiplatelet therapy
             can be maintained throughout the peri-surgical period.

          8. History of a stroke or transient ischemic attack (TIA) within 6 months prior to the
             index procedure.

          9. Subjects with active bleeding disorders, active coagulopathy, or any other reason, who
             are ineligible for DAPT.

         10. Subject will refuse blood transfusions.

         11. Subject has documented left ventricular ejection fraction (LVEF) &lt; 30% within 90 days
             prior to the index procedure.

         12. Subject is dialysis-dependent.

         13. Subject has impaired renal function (i.e., blood creatinine &gt; 2.5 mg/dL or 221 Î¼mol/L
             determined within 7 days prior to the index procedure).

         14. Subject has leukopenia (i.e. &lt; 3,000 white blood cells/mm3), thrombocytopenia (i.e. &lt;
             100,000 platelets/mm3) or thrombocytosis (i.e. &gt; 700,000 platelet/mm3).

         15. Subject is receiving oral or intravenous immunosuppressive therapy (inhaled steroids
             are permitted), or has known life-limiting immunosuppressive or autoimmune disease
             (e.g., human immunodeficiency virus, systemic lupus erythematosus; diabetes mellitus
             is permitted).

         16. Subject is receiving chronic anticoagulation (e.g. coumadin, dabigatran, apixaban,
             rivaroxaban or any other agent).

         17. Subject has life expectancy of &lt; 1 year.

         18. Subject is participating in another investigational (medical device or drug) clinical
             study. Subjects may be concurrently enrolled in a post-market study, as long as the
             post-market study device, drug or protocol does not interfere with the investigational
             treatment or protocol of this study.

         19. In the investigator's opinion, subject will not be able to comply with the follow-up
             requirements.

        Subjects will be excluded from the trial if any of the target lesions/vessels meets any of
        the following angiographic criteria:

          1. Target lesion is located within a saphenous vein graft or arterial graft.

          2. Target lesion is a restenotic lesion that was previously treated with a bare metal or
             drug eluting stent (in-stent restenosis).

          3. Target lesion has any of the following characteristics:

               1. Lesion location is within the left main coronary artery, or within 3 mm of the
                  origin of the left anterior descending (LAD) or left circumflex (LCX).

               2. Involves a side branch of &gt; 2.0 mm in diameter. Note: Lesions within 3 mm of the
                  origin of the right coronary artery may be treated.

          4. Target vessel/lesion is excessively tortuous/angulated or is severely calcified, that
             would prevent complete inflation of an angioplasty balloon. This assessment should be
             based on visual estimation.

          5. Target vessel has angiographic evidence of thrombus.

          6. Target lesion is totally occluded (100% stenosis).

          7. Target vessel was treated with brachytherapy any time prior to the index procedure.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ron Waksman, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Medstar Washington Hospital Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>David Kandzari, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Piedmont Heart Institute</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jacques Koolen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Catharina Ziekenhuis</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Fairhope</city>
        <state>Alabama</state>
        <zip>36535</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Concord</city>
        <state>California</state>
        <zip>94520</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>La Mesa</city>
        <state>California</state>
        <zip>91942</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Laguna Hills</city>
        <state>California</state>
        <zip>92653</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Mission Viejo</city>
        <state>California</state>
        <zip>92691</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Clearwater</city>
        <state>Florida</state>
        <zip>33756</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hollywood</city>
        <state>Florida</state>
        <zip>33021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32803</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33613</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30309</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Urbana</city>
        <state>Illinois</state>
        <zip>61801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Fort Wayne</city>
        <state>Indiana</state>
        <zip>46845</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21218</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02120</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bay City</city>
        <state>Michigan</state>
        <zip>48708</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48236</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lansing</city>
        <state>Michigan</state>
        <zip>48912</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pontiac</city>
        <state>Michigan</state>
        <zip>48341</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Rochester</city>
        <state>Michigan</state>
        <zip>48307</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Troy</city>
        <state>Michigan</state>
        <zip>48085</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ypsilanti</city>
        <state>Michigan</state>
        <zip>48197</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55407</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68124</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hackensack</city>
        <state>New Jersey</state>
        <zip>07601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Neptune</city>
        <state>New Jersey</state>
        <zip>07753</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Newark</city>
        <state>New Jersey</state>
        <zip>07102</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Asheville</city>
        <state>North Carolina</state>
        <zip>28803</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Greensboro</city>
        <state>North Carolina</state>
        <zip>27401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Fargo</city>
        <state>North Dakota</state>
        <zip>58102</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45219</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44111</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Elyria</city>
        <state>Ohio</state>
        <zip>44035</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Toledo</city>
        <state>Ohio</state>
        <zip>43606</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Toledo</city>
        <state>Ohio</state>
        <zip>43608</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97225</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Butler</city>
        <state>Pennsylvania</state>
        <zip>16001</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Mechanicsburg</city>
        <state>Pennsylvania</state>
        <zip>17050</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Wynnewood</city>
        <state>Pennsylvania</state>
        <zip>19096</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>York</city>
        <state>Pennsylvania</state>
        <zip>17403</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Providence</city>
        <state>Rhode Island</state>
        <zip>02906</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Greenville</city>
        <state>South Carolina</state>
        <zip>29605</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Rock Hill</city>
        <state>South Carolina</state>
        <zip>29732</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Knoxville</city>
        <state>Tennessee</state>
        <zip>37934</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75226</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>McKinney</city>
        <state>Texas</state>
        <zip>75069</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tyler</city>
        <state>Texas</state>
        <zip>75701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22908</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Virginia Beach</city>
        <state>Virginia</state>
        <zip>23454</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Charleston</city>
        <state>West Virginia</state>
        <zip>25304</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Adelaide</city>
        <zip>SA 5011</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Genk</city>
        <zip>3600</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Roeselare</city>
        <zip>8800</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T2N 4Z6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Aarhus</city>
        <zip>8200</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bad Segeberg</city>
        <zip>23795</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Berlin</city>
        <zip>10249</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Berlin</city>
        <zip>10967</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hamburg</city>
        <zip>20246</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Minden</city>
        <zip>32429</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Neuss</city>
        <zip>41464</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Budapest</city>
        <zip>1085</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>PÃ©cs</city>
        <zip>7624</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Szeged</city>
        <zip>6720</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Haifa</city>
        <zip>31096</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Jerusalem</city>
        <zip>91120</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Petach Tikva</city>
        <zip>49101</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Rehovot</city>
        <zip>76100</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tel Aviv</city>
        <zip>64239</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Daegu</city>
        <zip>705-718</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Gwangju</city>
        <zip>501-757</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Seoul</city>
        <zip>110-744</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Seoul</city>
        <zip>135-720</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Seoul</city>
        <zip>137-701</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Breda</city>
        <zip>4818 CK</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Eindhoven</city>
        <zip>5623 EJ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Nieuwegein</city>
        <zip>3435 CM</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Auckland</city>
        <zip>1142</zip>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Barcelona</city>
        <zip>08907</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Madrid</city>
        <zip>28222</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Malaga</city>
        <zip>29010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sevilla</city>
        <zip>41071</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lausanne</city>
        <zip>1011</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Zurich</city>
        <zip>8063</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Zurich</city>
        <zip>8091</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Belgium</country>
    <country>Canada</country>
    <country>Denmark</country>
    <country>Germany</country>
    <country>Hungary</country>
    <country>Israel</country>
    <country>Korea, Republic of</country>
    <country>Netherlands</country>
    <country>New Zealand</country>
    <country>Spain</country>
    <country>Switzerland</country>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Doros G, Massaro JM, Kandzari DE, Waksman R, Koolen JJ, Cutlip DE, Mauri L. Rationale of a novel study design for the BIOFLOW V study, a prospective, randomized multicenter study to assess the safety and efficacy of the Orsiro sirolimus-eluting coronary stent system using a Bayesian approach. Am Heart J. 2017 Nov;193:35-45. doi: 10.1016/j.ahj.2017.08.001. Epub 2017 Aug 5.</citation>
    <PMID>29129253</PMID>
  </reference>
  <results_reference>
    <citation>Kandzari DE, Mauri L, Koolen JJ, Massaro JM, Doros G, Garcia-Garcia HM, Bennett J, Roguin A, Gharib EG, Cutlip DE, Waksman R; BIOFLOW V Investigators. Ultrathin, bioresorbable polymer sirolimus-eluting stents versus thin, durable polymer everolimus-eluting stents in patients undergoing coronary revascularisation (BIOFLOW V): a randomised trial. Lancet. 2017 Oct 21;390(10105):1843-1852. doi: 10.1016/S0140-6736(17)32249-3. Epub 2017 Aug 26. Erratum in: Lancet. 2017 Oct 21;390(10105):1832.</citation>
    <PMID>28851504</PMID>
  </results_reference>
  <results_reference>
    <citation>Kandzari DE, Koolen JJ, Doros G, Massaro JJ, Garcia-Garcia HM, Bennett J, Roguin A, Gharib EG, Cutlip DE, Waksman R; BIOFLOW V Investigators. Ultrathin Bioresorbable Polymer Sirolimus-Eluting Stents Versus Thin Durable Polymer Everolimus-Eluting Stents. J Am Coll Cardiol. 2018 Dec 25;72(25):3287-3297. doi: 10.1016/j.jacc.2018.09.019. Epub 2018 Sep 23.</citation>
    <PMID>30257191</PMID>
  </results_reference>
  <results_reference>
    <citation>Roguin A, Kandzari DE, Marcusohn E, Koolen JJ, Doros G, Massaro JM, Garcia-Garcia HM, Bennett J, Gharib EG, Cutlip DE, Waksman R. Subgroup Analysis Comparing Ultrathin, Bioresorbable Polymer Sirolimus-Eluting Stents Versus Thin, Durable Polymer Everolimus-Eluting Stents in Acute Coronary Syndrome Patients. Circ Cardiovasc Interv. 2018 Oct;11(10):e007331. doi: 10.1161/CIRCINTERVENTIONS.118.007331.</citation>
    <PMID>30354631</PMID>
  </results_reference>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>March 2, 2015</study_first_submitted>
  <study_first_submitted_qc>March 10, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 17, 2015</study_first_posted>
  <results_first_submitted>March 8, 2019</results_first_submitted>
  <results_first_submitted_qc>July 5, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">August 1, 2019</results_first_posted>
  <disposition_first_submitted>June 6, 2018</disposition_first_submitted>
  <disposition_first_submitted_qc>June 11, 2018</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">June 13, 2018</disposition_first_posted>
  <last_update_submitted>July 7, 2020</last_update_submitted>
  <last_update_submitted_qc>July 7, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 9, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Drug eluting coronary stents</keyword>
  <keyword>Sirolimus</keyword>
  <keyword>Bioabsorbable polymer</keyword>
  <keyword>DES</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Heart Diseases</mesh_term>
    <mesh_term>Acute Coronary Syndrome</mesh_term>
    <mesh_term>Atherosclerosis</mesh_term>
    <mesh_term>Angina Pectoris</mesh_term>
    <mesh_term>Ischemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sirolimus</mesh_term>
    <mesh_term>Everolimus</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>February 11, 2016</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/46/NCT02389946/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>September 14, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/46/NCT02389946/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Orsiro Sirolimus Coronary Stent System</title>
          <description>Intervention with a Orsiro DES.
Orsiro DES: Orsiro is a device/drug combination product composed of two components, a device (coronary stent system including a cobalt chromium stent platform), and a drug product (a formulation of sirolimus) contained in a bioabsorbable polymer coating.</description>
        </group>
        <group group_id="P2">
          <title>Xience Everolimus Coronary Stent System</title>
          <description>Intervention with a Xience DES.
Xience DES</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="884"/>
                <participants group_id="P2" count="450"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="860"/>
                <participants group_id="P2" count="435"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="24"/>
                <participants group_id="P2" count="15"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Orsiro Sirolimus Coronary Stent System</title>
          <description>Intervention with a Orsiro DES.
Orsiro DES: Orsiro is a device/drug combination product composed of two components, a device (coronary stent system including a cobalt chromium stent platform), and a drug product (a formulation of sirolimus) contained in a bioabsorbable polymer coating.</description>
        </group>
        <group group_id="B2">
          <title>Xience Everolimus Coronary Stent System</title>
          <description>Intervention with a Xience DES.
Xience DES</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="884"/>
            <count group_id="B2" value="450"/>
            <count group_id="B3" value="1334"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="64.5" spread="10.32"/>
                    <measurement group_id="B2" value="64.6" spread="10.67"/>
                    <measurement group_id="B3" value="64.5" spread="10.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="224"/>
                    <measurement group_id="B2" value="122"/>
                    <measurement group_id="B3" value="346"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="660"/>
                    <measurement group_id="B2" value="328"/>
                    <measurement group_id="B3" value="988"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="35"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="48"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="812"/>
                    <measurement group_id="B2" value="417"/>
                    <measurement group_id="B3" value="1229"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="37"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="29"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="42"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="37"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="792"/>
                    <measurement group_id="B2" value="406"/>
                    <measurement group_id="B3" value="1198"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Target Lesion Failure (TLF) at 12 Months Post-Index Procedure by Bayesian Estimation</title>
        <description>TLF is defined as all cardiac death, target vessel Q-wave or non-Q-wave myocardial infarction (MI), or clinically driven target lesion revascularization (TLR).</description>
        <time_frame>12-Months</time_frame>
        <population>Pre-specified Bayesian analysis: BIOFLOW-V intent-to-treat subjects who experienced the primary endpoint or had at least 330 days of follow-up and BIOFLOW-II (NCT01356888) and BIOFLOW-IV (NCT01939249) subjects who satisfied the BIOFLOW-V inclusion/exclusion criteria and experienced the primary endpoint or had at least 330 days of follow-up.</population>
        <group_list>
          <group group_id="O1">
            <title>Orsiro Sirolimus Coronary Stent System</title>
            <description>Intervention with a Orsiro DES.
Orsiro DES: Orsiro is a device/drug combination product composed of two components, a device (coronary stent system including a cobalt chromium stent platform), and a drug product (a formulation of sirolimus) contained in a bioabsorbable polymer coating.</description>
          </group>
          <group group_id="O2">
            <title>Xience Everolimus Coronary Stent System</title>
            <description>Intervention with a Xience DES.
Xience DES</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Target Lesion Failure (TLF) at 12 Months Post-Index Procedure by Bayesian Estimation</title>
          <description>TLF is defined as all cardiac death, target vessel Q-wave or non-Q-wave myocardial infarction (MI), or clinically driven target lesion revascularization (TLR).</description>
          <population>Pre-specified Bayesian analysis: BIOFLOW-V intent-to-treat subjects who experienced the primary endpoint or had at least 330 days of follow-up and BIOFLOW-II (NCT01356888) and BIOFLOW-IV (NCT01939249) subjects who satisfied the BIOFLOW-V inclusion/exclusion criteria and experienced the primary endpoint or had at least 330 days of follow-up.</population>
          <units>Percentage of participants</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="883"/>
                <count group_id="O2" value="427"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.32" spread="0.75"/>
                    <measurement group_id="O2" value="8.90" spread="1.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Bayesian calculation using a hierarchical model to incorporate data from previous BIOFLOW-II and BIOFLOW-IV trials.</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority of the 12-month TLF rate for the Orsiro stent vs. the Xience stent was assessed as the primary endpoint. The null hypothesis H0 was that the Orsiro stent would have a primary endpoint (12-month TLF) rate equal to or exceeding that of the Xience group by the non-inferiority margin or more. The alternative hypothesis HA was that the Orsiro stent would have a 12-month TLF rate less than the Xience group rate plus the non-inferiority margin of 3.85%.</non_inferiority_desc>
            <param_type>Posterior Probability of non-inferioriry</param_type>
            <param_value>100</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Lesions With Device Success</title>
        <description>Defined as attainment of &lt; 30% residual stenosis of the target lesion using the assigned study stent only.</description>
        <time_frame>Hospital Discharge (6-24 hours post-index procedure)</time_frame>
        <population>Device Success per lesion. Lesions that were not treated and lesions missing both site-reported and core lab-assessed percent residual stenosis were excluded from the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Orsiro Sirolimus Coronary Stent System</title>
            <description>Intervention with a Orsiro DES.
Orsiro DES: Orsiro is a device/drug combination product composed of two components, a device (coronary stent system including a cobalt chromium stent platform), and a drug product (a formulation of sirolimus) contained in a bioabsorbable polymer coating.</description>
          </group>
          <group group_id="O2">
            <title>Xience Everolimus Coronary Stent System</title>
            <description>Intervention with a Xience DES.
Xience DES</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Lesions With Device Success</title>
          <description>Defined as attainment of &lt; 30% residual stenosis of the target lesion using the assigned study stent only.</description>
          <population>Device Success per lesion. Lesions that were not treated and lesions missing both site-reported and core lab-assessed percent residual stenosis were excluded from the analysis.</population>
          <units>Lesions</units>
          <param>Number</param>
          <units_analyzed>Lesions</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="881"/>
                <count group_id="O2" value="445"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Lesions</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1107"/>
                <count group_id="O2" value="583"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1082"/>
                    <measurement group_id="O2" value="566"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.415</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Lesions With Lesion Success</title>
        <description>Defined as attainment of &lt; 30% residual stenosis of the target lesion using any percutaneous method.</description>
        <time_frame>Hospital Discharge (6-24 hours post-index procedure)</time_frame>
        <population>Lesion Success per lesion. Lesions that were not treated and lesions missing both site-reported and core lab-assessed percent residual stenosis were excluded from the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Orsiro Sirolimus Coronary Stent System</title>
            <description>Intervention with a Orsiro DES.
Orsiro DES: Orsiro is a device/drug combination product composed of two components, a device (coronary stent system including a cobalt chromium stent platform), and a drug product (a formulation of sirolimus) contained in a bioabsorbable polymer coating.</description>
          </group>
          <group group_id="O2">
            <title>Xience Everolimus Coronary Stent System</title>
            <description>Intervention with a Xience DES.
Xience DES</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Lesions With Lesion Success</title>
          <description>Defined as attainment of &lt; 30% residual stenosis of the target lesion using any percutaneous method.</description>
          <population>Lesion Success per lesion. Lesions that were not treated and lesions missing both site-reported and core lab-assessed percent residual stenosis were excluded from the analysis.</population>
          <units>Lesions</units>
          <param>Count of Units</param>
          <units_analyzed>Lesions</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="881"/>
                <count group_id="O2" value="445"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Lesions</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1107"/>
                <count group_id="O2" value="583"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1102"/>
                    <measurement group_id="O2" value="579"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Procedure Success</title>
        <description>Defined as attainment of &lt; 30% residual stenosis of the target lesion using the assigned study stent only without occurrence of in-hospital major adverse cardiac events (MACE; composite of all-cause death, Q-wave or non-Q-wave MI, and any clinically-driven TLR).</description>
        <time_frame>Hospital Discharge (6-24 hours post-index procedure)</time_frame>
        <population>Procedure success was analyzed per subject: for a subject to be considered a procedure success, all of the subject's target lesions had to be considered device success. Lesions that were not treated and lesions missing both site-reported and core lab-assessed percent residual stenosis were excluded from the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Orsiro Sirolimus Coronary Stent System</title>
            <description>Intervention with a Orsiro DES.
Orsiro DES: Orsiro is a device/drug combination product composed of two components, a device (coronary stent system including a cobalt chromium stent platform), and a drug product (a formulation of sirolimus) contained in a bioabsorbable polymer coating.</description>
          </group>
          <group group_id="O2">
            <title>Xience Everolimus Coronary Stent System</title>
            <description>Intervention with a Xience DES.
Xience DES</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Procedure Success</title>
          <description>Defined as attainment of &lt; 30% residual stenosis of the target lesion using the assigned study stent only without occurrence of in-hospital major adverse cardiac events (MACE; composite of all-cause death, Q-wave or non-Q-wave MI, and any clinically-driven TLR).</description>
          <population>Procedure success was analyzed per subject: for a subject to be considered a procedure success, all of the subject's target lesions had to be considered device success. Lesions that were not treated and lesions missing both site-reported and core lab-assessed percent residual stenosis were excluded from the analysis.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="881"/>
                <count group_id="O2" value="445"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="827"/>
                    <measurement group_id="O2" value="401"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Myocardial Infarction</title>
        <time_frame>Hospital Discharge (6-24 hours post-index procedure), 1, 6, 12 months, 2, 3, 4 and 5 years</time_frame>
        <posting_date>04/2022</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Myocardial Infarction or Cardiac Death</title>
        <description>Anticipated reporting: April 2022.</description>
        <time_frame>Hospital Discharge (6-24 hours post-index procedure), 1, 6, 12 months, 2, 3, 4 and 5 years</time_frame>
        <posting_date>04/2022</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With MACE and Individual MACE Components</title>
        <description>MACE: composite of all-cause death, Q-wave or non-Q-wave MI, and any clinically-driven TLR</description>
        <time_frame>Hospital Discharge (6-24 hours post-index procedure), 1, 6, 12 months, 2, 3, 4 and 5 years</time_frame>
        <posting_date>04/2022</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With TLF and Individual TLF Components</title>
        <description>TLF: composite of cardiac death, target vessel Q-wave or non-Q-wave MI, and any clinically-driven TLR</description>
        <time_frame>Hospital Discharge (6-24 hours post-index procedure), 1, 6, 12 months, 2, 3, 4 and 5 years</time_frame>
        <posting_date>04/2022</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Target Vessel Failure (TVF) and Individual TVF Components</title>
        <description>TVF: composite of cardiac death, target vessel Q-wave or non-Q-wave MI, and any clinically-driven TVR.</description>
        <time_frame>Hospital Discharge (6-24 hours post-index procedure), 1, 6, 12 months, 2, 3, 4 and 5 years</time_frame>
        <posting_date>04/2022</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Stent Thrombosis</title>
        <description>Stent thrombosis according to the Academic Research Consortium criteria.</description>
        <time_frame>Hospital Discharge (6-24 hours post-index procedure), 1, 6, 12 months, 2, 3, 4 and 5 years</time_frame>
        <posting_date>04/2022</posting_date>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>1 year</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Orsiro Sirolimus Coronary Stent System</title>
          <description>Intervention with a Orsiro DES.
Orsiro DES: Orsiro is a device/drug combination product composed of two components, a device (coronary stent system including a cobalt chromium stent platform), and a drug product (a formulation of sirolimus) contained in a bioabsorbable polymer coating.</description>
        </group>
        <group group_id="E2">
          <title>Xience Everolimus Coronary Stent System</title>
          <description>Intervention with a Xience DES.
Xience DES</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="884"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="450"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="307" subjects_at_risk="884"/>
                <counts group_id="E2" subjects_affected="161" subjects_at_risk="450"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="884"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="450"/>
              </event>
              <event>
                <sub_title>Haemorrhagic anaemia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="884"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="450"/>
              </event>
              <event>
                <sub_title>Iron deficiency anaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="884"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="450"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="884"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="450"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute coronary syndrome</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="884"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="450"/>
              </event>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" events="17" subjects_affected="9" subjects_at_risk="884"/>
                <counts group_id="E2" events="9" subjects_affected="7" subjects_at_risk="450"/>
              </event>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" events="52" subjects_affected="45" subjects_at_risk="884"/>
                <counts group_id="E2" events="22" subjects_affected="20" subjects_at_risk="450"/>
              </event>
              <event>
                <sub_title>Angina unstable</sub_title>
                <counts group_id="E1" events="33" subjects_affected="27" subjects_at_risk="884"/>
                <counts group_id="E2" events="12" subjects_affected="12" subjects_at_risk="450"/>
              </event>
              <event>
                <sub_title>Arteriosclerosis coronary artery</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="884"/>
                <counts group_id="E2" events="6" subjects_affected="2" subjects_at_risk="450"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" events="15" subjects_affected="13" subjects_at_risk="884"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="450"/>
              </event>
              <event>
                <sub_title>Atrial flutter</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="884"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="450"/>
              </event>
              <event>
                <sub_title>Atrial tachycardia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="884"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="450"/>
              </event>
              <event>
                <sub_title>Atrioventricular block complete</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="884"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="450"/>
              </event>
              <event>
                <sub_title>Bradycardia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="884"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="450"/>
              </event>
              <event>
                <sub_title>Cardiac arrest</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="884"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="450"/>
              </event>
              <event>
                <sub_title>Cardiac failure acute</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="884"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="450"/>
              </event>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="884"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="450"/>
              </event>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="884"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="450"/>
              </event>
              <event>
                <sub_title>Cardiac pseudoaneurysm</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="884"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="450"/>
              </event>
              <event>
                <sub_title>Cardiac tamponade</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="884"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="450"/>
              </event>
              <event>
                <sub_title>Cardiomyopathy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="884"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="450"/>
              </event>
              <event>
                <sub_title>Coronary artery disease</sub_title>
                <counts group_id="E1" events="9" subjects_affected="6" subjects_at_risk="884"/>
                <counts group_id="E2" events="9" subjects_affected="6" subjects_at_risk="450"/>
              </event>
              <event>
                <sub_title>Coronary artery dissection</sub_title>
                <counts group_id="E1" events="23" subjects_affected="22" subjects_at_risk="884"/>
                <counts group_id="E2" events="23" subjects_affected="21" subjects_at_risk="450"/>
              </event>
              <event>
                <sub_title>Coronary artery embolism</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="884"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="450"/>
              </event>
              <event>
                <sub_title>Coronary artery occlusion</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="884"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="450"/>
              </event>
              <event>
                <sub_title>Coronary artery stenosis</sub_title>
                <counts group_id="E1" events="27" subjects_affected="18" subjects_at_risk="884"/>
                <counts group_id="E2" events="12" subjects_affected="10" subjects_at_risk="450"/>
              </event>
              <event>
                <sub_title>Diastolic dysfunction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="884"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="450"/>
              </event>
              <event>
                <sub_title>Ischaemic cardiomyopathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="884"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="450"/>
              </event>
              <event>
                <sub_title>Left ventricular dysfunction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="884"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="450"/>
              </event>
              <event>
                <sub_title>Microvascular coronary artery disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="884"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="450"/>
              </event>
              <event>
                <sub_title>Mitral valve prolapse</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="884"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="450"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="884"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="450"/>
              </event>
              <event>
                <sub_title>Myocardial rupture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="884"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="450"/>
              </event>
              <event>
                <sub_title>Pericarditis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="884"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="450"/>
              </event>
              <event>
                <sub_title>Prinzmetal angina</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="884"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="450"/>
              </event>
              <event>
                <sub_title>Sinus arrest</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="884"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="450"/>
              </event>
              <event>
                <sub_title>Sinus node dysfunction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="884"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="450"/>
              </event>
              <event>
                <sub_title>Supraventricular tachycardia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="884"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="450"/>
              </event>
              <event>
                <sub_title>Ventricular extrasystoles</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="884"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="450"/>
              </event>
              <event>
                <sub_title>Ventricular fibrillation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="884"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="450"/>
              </event>
              <event>
                <sub_title>Ventricular tachycardia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="884"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="450"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertrophic cardiomyopathy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="884"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="450"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Cataract</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="884"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="450"/>
              </event>
              <event>
                <sub_title>Retinal detachment</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="884"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="450"/>
              </event>
              <event>
                <sub_title>Visual acuity reduced</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="884"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="450"/>
              </event>
              <event>
                <sub_title>Visual impairment</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="884"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="450"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal hernia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="884"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="450"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="884"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="450"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="884"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="450"/>
              </event>
              <event>
                <sub_title>Alcoholic pancreatitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="884"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="450"/>
              </event>
              <event>
                <sub_title>Anal haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="884"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="450"/>
              </event>
              <event>
                <sub_title>Chronic gastritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="884"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="450"/>
              </event>
              <event>
                <sub_title>Colitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="884"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="450"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="884"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="450"/>
              </event>
              <event>
                <sub_title>Diverticulum</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="884"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="450"/>
              </event>
              <event>
                <sub_title>Dysphagia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="884"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="450"/>
              </event>
              <event>
                <sub_title>Gastric haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="884"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="450"/>
              </event>
              <event>
                <sub_title>Gastritis haemorrhagic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="884"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="450"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="884"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="450"/>
              </event>
              <event>
                <sub_title>Gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="884"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="450"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="884"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="450"/>
              </event>
              <event>
                <sub_title>Haematochezia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="884"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="450"/>
              </event>
              <event>
                <sub_title>Incarcerated umbilical hernia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="884"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="450"/>
              </event>
              <event>
                <sub_title>Intestinal angina</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="884"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="450"/>
              </event>
              <event>
                <sub_title>Large intestinal obstruction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="884"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="450"/>
              </event>
              <event>
                <sub_title>Melaena</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="884"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="450"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="884"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="450"/>
              </event>
              <event>
                <sub_title>Odynophagia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="884"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="450"/>
              </event>
              <event>
                <sub_title>Oesophageal rupture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="884"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="450"/>
              </event>
              <event>
                <sub_title>Pancreatitis acute</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="884"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="450"/>
              </event>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="884"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="450"/>
              </event>
              <event>
                <sub_title>Peptic ulcer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="884"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="450"/>
              </event>
              <event>
                <sub_title>Rectal haemorrhage</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="884"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="450"/>
              </event>
              <event>
                <sub_title>Rectal polyp</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="884"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="450"/>
              </event>
              <event>
                <sub_title>Retroperitoneal haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="884"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="450"/>
              </event>
              <event>
                <sub_title>Retroperitoneal mass</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="884"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="450"/>
              </event>
              <event>
                <sub_title>Small intestinal obstruction</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="884"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="450"/>
              </event>
              <event>
                <sub_title>Stomach granuloma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="884"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="450"/>
              </event>
              <event>
                <sub_title>Tongue haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="884"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="450"/>
              </event>
              <event>
                <sub_title>Upper gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="884"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="450"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="884"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="450"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Accidental death</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="884"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="450"/>
              </event>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="884"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="450"/>
              </event>
              <event>
                <sub_title>Catheter site haematoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="884"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="450"/>
              </event>
              <event>
                <sub_title>Catheter site haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="884"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="450"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" events="15" subjects_affected="14" subjects_at_risk="884"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="450"/>
              </event>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="884"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="450"/>
              </event>
              <event>
                <sub_title>Incarcerated hernia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="884"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="450"/>
              </event>
              <event>
                <sub_title>Multi-organ failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="884"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="450"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" events="66" subjects_affected="58" subjects_at_risk="884"/>
                <counts group_id="E2" events="25" subjects_affected="22" subjects_at_risk="450"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="884"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="450"/>
              </event>
              <event>
                <sub_title>Vascular stent restenosis</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="884"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="450"/>
              </event>
              <event>
                <sub_title>Vascular stent stenosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="884"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="450"/>
              </event>
              <event>
                <sub_title>Vascular stent thrombosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="884"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="450"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholecystitis acute</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="884"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="450"/>
              </event>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="884"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="450"/>
              </event>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="884"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="450"/>
              </event>
              <event>
                <sub_title>Hepatitis alcoholic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="884"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="450"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Allergic oedema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="884"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="450"/>
              </event>
              <event>
                <sub_title>Serum sickness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="884"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="450"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Abdominal wall abscess</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="884"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="450"/>
              </event>
              <event>
                <sub_title>Abscess limb</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="884"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="450"/>
              </event>
              <event>
                <sub_title>Anal abscess</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="884"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="450"/>
              </event>
              <event>
                <sub_title>Beta haemolytic streptococcal infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="884"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="450"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="884"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="450"/>
              </event>
              <event>
                <sub_title>Catheter site abscess</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="884"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="450"/>
              </event>
              <event>
                <sub_title>Cellulitis streptococcal</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="884"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="450"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="884"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="450"/>
              </event>
              <event>
                <sub_title>Cholecystitis infective</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="884"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="450"/>
              </event>
              <event>
                <sub_title>Clostridium difficile colitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="884"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="450"/>
              </event>
              <event>
                <sub_title>Emphysematous cholecystitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="884"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="450"/>
              </event>
              <event>
                <sub_title>Enteritis infectious</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="884"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="450"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="884"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="450"/>
              </event>
              <event>
                <sub_title>Herpes zoster</sub_title>
                <counts group_id="E1" events="3" subjects_affected="1" subjects_at_risk="884"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="450"/>
              </event>
              <event>
                <sub_title>Peritonitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="884"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="450"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="884"/>
                <counts group_id="E2" events="5" subjects_affected="4" subjects_at_risk="450"/>
              </event>
              <event>
                <sub_title>Pulmonary sepsis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="884"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="450"/>
              </event>
              <event>
                <sub_title>Scrotal abscess</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="884"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="450"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="884"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="450"/>
              </event>
              <event>
                <sub_title>Septic shock</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="884"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="450"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="884"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="450"/>
              </event>
              <event>
                <sub_title>Staphylococcal infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="884"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="450"/>
              </event>
              <event>
                <sub_title>Tooth abscess</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="884"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="450"/>
              </event>
              <event>
                <sub_title>Tuberculosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="884"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="450"/>
              </event>
              <event>
                <sub_title>Urinary tract infection enterococcal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="884"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="450"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="884"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="450"/>
              </event>
              <event>
                <sub_title>Vestibular neuronitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="884"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="450"/>
              </event>
              <event>
                <sub_title>Viral infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="884"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="450"/>
              </event>
              <event>
                <sub_title>Wound infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="884"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="450"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Ankle fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="884"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="450"/>
              </event>
              <event>
                <sub_title>Asbestosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="884"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="450"/>
              </event>
              <event>
                <sub_title>Cardiac procedure complication</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="884"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="450"/>
              </event>
              <event>
                <sub_title>Chest injury</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="884"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="450"/>
              </event>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="884"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="450"/>
              </event>
              <event>
                <sub_title>Coronary artery restenosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="884"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="450"/>
              </event>
              <event>
                <sub_title>Femur fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="884"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="450"/>
              </event>
              <event>
                <sub_title>Foot fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="884"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="450"/>
              </event>
              <event>
                <sub_title>Intentional overdose</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="884"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="450"/>
              </event>
              <event>
                <sub_title>Laceration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="884"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="450"/>
              </event>
              <event>
                <sub_title>Lumbar vertebral fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="884"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="450"/>
              </event>
              <event>
                <sub_title>Meniscus injury</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="884"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="450"/>
              </event>
              <event>
                <sub_title>Patella fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="884"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="450"/>
              </event>
              <event>
                <sub_title>Radius fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="884"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="450"/>
              </event>
              <event>
                <sub_title>Rib fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="884"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="450"/>
              </event>
              <event>
                <sub_title>Subdural haematoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="884"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="450"/>
              </event>
              <event>
                <sub_title>Thoracic vertebral fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="884"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="450"/>
              </event>
              <event>
                <sub_title>Tibia fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="884"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="450"/>
              </event>
              <event>
                <sub_title>Traumatic haematoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="884"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="450"/>
              </event>
              <event>
                <sub_title>Upper limb fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="884"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="450"/>
              </event>
              <event>
                <sub_title>Urinary retention postoperative</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="884"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="450"/>
              </event>
              <event>
                <sub_title>Vascular pseudoaneurysm</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="884"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="450"/>
              </event>
              <event>
                <sub_title>Wound dehiscence</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="884"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="450"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood creatinine increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="884"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="450"/>
              </event>
              <event>
                <sub_title>Cardiac stress test abnormal</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="884"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="450"/>
              </event>
              <event>
                <sub_title>Haemoglobin decreased</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="884"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="450"/>
              </event>
              <event>
                <sub_title>Myocardial necrosis marker increased</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="884"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="450"/>
              </event>
              <event>
                <sub_title>Prostatic specific antigen increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="884"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="450"/>
              </event>
              <event>
                <sub_title>Troponin increased</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="884"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="450"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Diabetes mellitus inadequate control</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="884"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="450"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="884"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="450"/>
              </event>
              <event>
                <sub_title>Hyperkalaemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="884"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="450"/>
              </event>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="884"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="450"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="884"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="450"/>
              </event>
              <event>
                <sub_title>Hypomagnesaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="884"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="450"/>
              </event>
              <event>
                <sub_title>Hyponatraemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="884"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="450"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="884"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="450"/>
              </event>
              <event>
                <sub_title>Arthritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="884"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="450"/>
              </event>
              <event>
                <sub_title>Bone pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="884"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="450"/>
              </event>
              <event>
                <sub_title>Bursitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="884"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="450"/>
              </event>
              <event>
                <sub_title>Compartment syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="884"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="450"/>
              </event>
              <event>
                <sub_title>Costochondritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="884"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="450"/>
              </event>
              <event>
                <sub_title>Intervertebral disc degeneration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="884"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="450"/>
              </event>
              <event>
                <sub_title>Intervertebral disc protrusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="884"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="450"/>
              </event>
              <event>
                <sub_title>Lumbar spinal stenosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="884"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="450"/>
              </event>
              <event>
                <sub_title>Muscle spasms</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="884"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="450"/>
              </event>
              <event>
                <sub_title>Musculoskeletal chest pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="884"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="450"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="884"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="450"/>
              </event>
              <event>
                <sub_title>Neck pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="884"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="450"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="884"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="450"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="884"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="450"/>
              </event>
              <event>
                <sub_title>Rheumatoid arthritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="884"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="450"/>
              </event>
              <event>
                <sub_title>Rotator cuff syndrome</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="884"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="450"/>
              </event>
              <event>
                <sub_title>Spinal osteoarthritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="884"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="450"/>
              </event>
              <event>
                <sub_title>Spondylitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="884"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="450"/>
              </event>
              <event>
                <sub_title>Tenosynovitis stenosans</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="884"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="450"/>
              </event>
              <event>
                <sub_title>Vertebral foraminal stenosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="884"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="450"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Basal cell carcinoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="884"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="450"/>
              </event>
              <event>
                <sub_title>Bladder cancer</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="884"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="450"/>
              </event>
              <event>
                <sub_title>Breast cancer</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="884"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="450"/>
              </event>
              <event>
                <sub_title>Cervix carcinoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="884"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="450"/>
              </event>
              <event>
                <sub_title>Leiomyoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="884"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="450"/>
              </event>
              <event>
                <sub_title>Lung carcinoma cell type unspecified stage IV</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="884"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="450"/>
              </event>
              <event>
                <sub_title>Lung neoplasm malignant</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="884"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="450"/>
              </event>
              <event>
                <sub_title>Malignant melanoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="884"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="450"/>
              </event>
              <event>
                <sub_title>Metastatic neoplasm</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="884"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="450"/>
              </event>
              <event>
                <sub_title>Prostate cancer metastatic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="884"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="450"/>
              </event>
              <event>
                <sub_title>Prostate cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="884"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="450"/>
              </event>
              <event>
                <sub_title>Rectosigmoid cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="884"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="450"/>
              </event>
              <event>
                <sub_title>Renal cell carcinoma</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="884"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="450"/>
              </event>
              <event>
                <sub_title>Seborrhoeic keratosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="884"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="450"/>
              </event>
              <event>
                <sub_title>Skin cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="884"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="450"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Altered state of consciousness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="884"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="450"/>
              </event>
              <event>
                <sub_title>Carotid artery disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="884"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="450"/>
              </event>
              <event>
                <sub_title>Carotid artery stenosis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="884"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="450"/>
              </event>
              <event>
                <sub_title>Carpal tunnel syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="884"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="450"/>
              </event>
              <event>
                <sub_title>Cerebral haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="884"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="450"/>
              </event>
              <event>
                <sub_title>Cerebral infarction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="884"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="450"/>
              </event>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="884"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="450"/>
              </event>
              <event>
                <sub_title>Diabetic neuropathy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="884"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="450"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="884"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="450"/>
              </event>
              <event>
                <sub_title>Embolic stroke</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="884"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="450"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="884"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="450"/>
              </event>
              <event>
                <sub_title>Ischaemic stroke</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="884"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="450"/>
              </event>
              <event>
                <sub_title>Migraine</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="884"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="450"/>
              </event>
              <event>
                <sub_title>Myoclonus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="884"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="450"/>
              </event>
              <event>
                <sub_title>Neuropathy peripheral</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="884"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="450"/>
              </event>
              <event>
                <sub_title>Paraesthesia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="884"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="450"/>
              </event>
              <event>
                <sub_title>Presyncope</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="884"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="450"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="884"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="450"/>
              </event>
              <event>
                <sub_title>Thalamic infarction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="884"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="450"/>
              </event>
              <event>
                <sub_title>Transient ischaemic attack</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="884"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="450"/>
              </event>
              <event>
                <sub_title>VIIth nerve paralysis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="884"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="450"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Confusional state</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="884"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="450"/>
              </event>
              <event>
                <sub_title>Delirium</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="884"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="450"/>
              </event>
              <event>
                <sub_title>Major depression</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="884"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="450"/>
              </event>
              <event>
                <sub_title>Mental status changes</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="884"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="450"/>
              </event>
              <event>
                <sub_title>Suicidal ideation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="884"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="450"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute kidney injury</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="884"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="450"/>
              </event>
              <event>
                <sub_title>Calculus bladder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="884"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="450"/>
              </event>
              <event>
                <sub_title>Calculus ureteric</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="884"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="450"/>
              </event>
              <event>
                <sub_title>Chronic kidney disease</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="884"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="450"/>
              </event>
              <event>
                <sub_title>Cystitis haemorrhagic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="884"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="450"/>
              </event>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="884"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="450"/>
              </event>
              <event>
                <sub_title>Hydronephrosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="884"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="450"/>
              </event>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="884"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="450"/>
              </event>
              <event>
                <sub_title>Renal cyst</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="884"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="450"/>
              </event>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="884"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="450"/>
              </event>
              <event>
                <sub_title>Renal mass</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="884"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="450"/>
              </event>
              <event>
                <sub_title>Urinary retention</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="884"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="450"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Acute respiratory distress syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="884"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="450"/>
              </event>
              <event>
                <sub_title>Acute respiratory failure</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="884"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="450"/>
              </event>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="884"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="450"/>
              </event>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="884"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="450"/>
              </event>
              <event>
                <sub_title>Dyspnoea exertional</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="884"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="450"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" events="16" subjects_affected="14" subjects_at_risk="884"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="450"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="884"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="450"/>
              </event>
              <event>
                <sub_title>Haemoptysis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="884"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="450"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="884"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="450"/>
              </event>
              <event>
                <sub_title>Pleuritic pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="884"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="450"/>
              </event>
              <event>
                <sub_title>Pneumonitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="884"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="450"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="884"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="450"/>
              </event>
              <event>
                <sub_title>Pulmonary fibrosis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="884"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="450"/>
              </event>
              <event>
                <sub_title>Pulmonary hypertension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="884"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="450"/>
              </event>
              <event>
                <sub_title>Pulmonary mass</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="884"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="450"/>
              </event>
              <event>
                <sub_title>Pulmonary oedema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="884"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="450"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="884"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="450"/>
              </event>
              <event>
                <sub_title>Sleep apnoea syndrome</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="884"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="450"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dermatitis allergic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="884"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="450"/>
              </event>
              <event>
                <sub_title>Diffuse cutaneous mastocytosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="884"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="450"/>
              </event>
              <event>
                <sub_title>Pruritus allergic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="884"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="450"/>
              </event>
              <event>
                <sub_title>Rash generalised</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="884"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="450"/>
              </event>
              <event>
                <sub_title>Red man syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="884"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="450"/>
              </event>
              <event>
                <sub_title>Skin ulcer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="884"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="450"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Aortic aneurysm</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="884"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="450"/>
              </event>
              <event>
                <sub_title>Aortic stenosis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="884"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="450"/>
              </event>
              <event>
                <sub_title>Femoral artery dissection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="884"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="450"/>
              </event>
              <event>
                <sub_title>Haemodynamic instability</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="884"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="450"/>
              </event>
              <event>
                <sub_title>Haemorrhage</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="884"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="450"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="884"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="450"/>
              </event>
              <event>
                <sub_title>Hypertensive crisis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="884"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="450"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="884"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="450"/>
              </event>
              <event>
                <sub_title>Iliac artery occlusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="884"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="450"/>
              </event>
              <event>
                <sub_title>Intermittent claudication</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="884"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="450"/>
              </event>
              <event>
                <sub_title>Lymphoedema</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="884"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="450"/>
              </event>
              <event>
                <sub_title>Peripheral arterial occlusive disease</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="884"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="450"/>
              </event>
              <event>
                <sub_title>Peripheral artery stenosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="884"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="450"/>
              </event>
              <event>
                <sub_title>Peripheral ischaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="884"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="450"/>
              </event>
              <event>
                <sub_title>Peripheral vascular disorder</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="884"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="450"/>
              </event>
              <event>
                <sub_title>Subclavian artery stenosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="884"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="450"/>
              </event>
              <event>
                <sub_title>Varicose vein</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="884"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="450"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="291" subjects_at_risk="884"/>
                <counts group_id="E2" subjects_affected="165" subjects_at_risk="450"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" subjects_affected="52" subjects_at_risk="884"/>
                <counts group_id="E2" subjects_affected="40" subjects_at_risk="450"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" subjects_affected="65" subjects_at_risk="884"/>
                <counts group_id="E2" subjects_affected="36" subjects_at_risk="450"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Myocardial necrosis marker increased</sub_title>
                <counts group_id="E1" subjects_affected="167" subjects_at_risk="884"/>
                <counts group_id="E2" subjects_affected="89" subjects_at_risk="450"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="58" subjects_at_risk="884"/>
                <counts group_id="E2" subjects_affected="27" subjects_at_risk="450"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Amy Culley, Director of Vascular Intervention Clinical Studies</name_or_title>
      <organization>BIOTRONIK, Inc</organization>
      <phone>503-451-8034</phone>
      <email>amy.culley@biotronik.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

